This is a standard independent director appointment with no trading signal. No further action warranted, monitor for any future association with Philips-related partnerships or M&A, but not an event for immediate positioning.
GSK drugs
GSK drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 9 $52.47entry
- T+1 · 4mo ago +0.59%α +0.16% · $52.78
- T+5 · 4mo ago +0.57%α +0.70% · $52.77
- T+20 · 3mo ago −0.57%α −2.81% · $52.17
- T+60 · 7w ago −10.37%α −12.00% · $47.03
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
GSK announced the appointment of Roy Jakobs, CEO of Royal Philips, as an independent Non-Executive Director effective July 13, 2026. This is a routine board addition bringing health technology expertise, with no material financial impact or strategic change.
Key Facts
- Roy Jakobs to join GSK board as independent Non-Executive Director from July 13, 2026
- Jakobs is currently CEO of Royal Philips (EUR 17.8B sales in 2025, 65,000 employees)
- Standard annual fee of £122,258 for the non-executive role
- Board expands to 13 members as of the effective date
Financial Impact
No material financial figures; annual director fee of £122,258 is immaterial for a $106B market cap company
Risk Factors
- None identified from this filing alone
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-006557 |
| Document: 0001654954-26-006557-index-headers.html | 0001654954-26-006557 |
| Document: 0001654954-26-006557-index.html | 0001654954-26-006557 |
| Document: 0001654954-26-006557.txt | 0001654954-26-006557 |
Track record
64 reports on GSK
9 of 18 bullish or bearish reports moved the stock their way by T+20. Best: +9.35% at T+60 after the Jul 17, 2026 report. 15 of 21 went positive at some point.
Filters
- Nov 13, 20263d ago 6-K Neutral 4/10 Entry $50.45 Now $50.41 −0.08% settles Dec 14
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $50.64 Now $50.41 −0.45% settles Dec 11
- Nov 6, 202610d ago 6-K Neutral 1/10 Entry $50.33 Now $50.41 +0.16% settles Dec 7
- Nov 2, 202614d ago 6-K Neutral 1/10 Entry $49.13 Now $50.41 +2.61% settles Dec 1
- Oct 28, 202619d ago 6-K Neutral 5/10 Entry $48.74 Now $50.41 +3.43% settles Nov 25
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Neutral 1/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Neutral 4/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 21, 202626d ago 6-K Bullish 7/10 Entry $50.02 Now $50.41 +0.78% settles Nov 18
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers